How Many Small-Cell Lung Cancers Express Somatostatin Receptors for Peptide Therapy?
Only 29.4% of small-cell lung cancer samples expressed somatostatin receptor subtype 2, suggesting peptide receptor radionuclide therapy may benefit a limited but identifiable subset of patients.
Quick Facts
What This Study Found
SSTR1 was absent in all SCLC samples. SSTR2 was expressed in 29.4% and SSTR3 in 4.35% of cases. Co-expression of SSTR2 and SSTR3 occurred in 5.3% of patients. Female patients showed a trend toward higher expression, and older patients trended toward lower SSTR2 expression, but neither reached statistical significance. Disease stage did not correlate with receptor expression.
Key Numbers
SSTR subtypes 1, 2, and 3 were analyzed using immunohistochemistry on SCLC tissue samples.
How They Did This
Tissue microarray analysis of 147 paraffin-embedded SCLC samples. Immunohistochemistry using anti-SSTR1, SSTR2, and SSTR3 antibodies, calibrated with healthy human pancreatic islets as positive controls. Slides scored by stain intensity and percentage of stained cells.
Why This Research Matters
Somatostatin analogue therapy and peptide receptor radionuclide therapy (PRRT) require the tumor to express somatostatin receptors. This study shows that while not all SCLC patients are candidates, nearly a third express SSTR2 — making screening worthwhile for identifying patients who could benefit from peptide-targeted treatments.
The Bigger Picture
Peptide receptor radionuclide therapy has transformed treatment for neuroendocrine tumors. Extending this approach to SCLC could provide a new therapeutic option, but patient screening for somatostatin receptor expression is essential for identifying who would benefit.
What This Study Doesn't Tell Us
Retrospective tissue analysis without clinical outcomes data — receptor expression doesn't guarantee therapeutic response. Sample size of 147 is moderate. No predictors of expression reached statistical significance. Only three SSTR subtypes were tested; SSTR4 and SSTR5 were not assessed.
Questions This Raises
- ?Would SSTR2-positive SCLC patients respond to peptide receptor radionuclide therapy?
- ?Are SSTR4 or SSTR5 expressed in SCLC and could they serve as additional targets?
- ?Could SSTR expression be used as a prognostic marker in SCLC?
Trust & Context
- Key Stat:
- 29.4% SSTR2 expression Nearly a third of small-cell lung cancer samples expressed somatostatin receptor 2, the main target for peptide receptor radionuclide therapy
- Evidence Grade:
- Rated preliminary: tissue expression study without clinical treatment outcomes. Establishes receptor presence but doesn't demonstrate therapeutic efficacy.
- Study Age:
- Published in 2024. Contributes to the growing evidence base for expanding somatostatin-targeted therapies beyond traditional neuroendocrine tumors.
- Original Title:
- Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.
- Published In:
- Anticancer research, 44(9), 3807-3812 (2024)
- Database ID:
- RPEP-09188
Evidence Hierarchy
Frequently Asked Questions
Can somatostatin-based therapy work for lung cancer?
About 29% of small-cell lung cancers express the somatostatin receptor needed for peptide-targeted treatments, suggesting it could work for a subset of patients, but clinical trials are needed.
What is peptide receptor radionuclide therapy?
PRRT uses radioactive somatostatin analogues (peptides) that bind to somatostatin receptors on tumor cells, delivering radiation directly to the cancer while sparing healthy tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09188APA
Sagie, Nitzan; Romanov, Elizabeth; Kezerle, Yarden; Meirovitz, Amichay; Sheva, Kim. (2024). Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.. Anticancer research, 44(9), 3807-3812. https://doi.org/10.21873/anticanres.17206
MLA
Sagie, Nitzan, et al. "Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.." Anticancer research, 2024. https://doi.org/10.21873/anticanres.17206
RethinkPeptides
RethinkPeptides Research Database. "Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Ca..." RPEP-09188. Retrieved from https://rethinkpeptides.com/research/sagie-2024-expression-analysis-of-sstr
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.